$德纳维制药(DVAX)$ Dynavax’s SD-101 in Combination with KEYTRUDA® (pembrolizumab) ****Continues***** to Show a 70% Overall Response Rate in Advanced Melanoma Patients According to Data Presented Today at the ESMO 2018 Congress

esmo: c1/2mg, 1-4 lesions, 33/47, 70%; c2/8mg, single lesion, 48% = 19/40; (87pts)
asco: c1, 21/30, 70%; c2, 15/39, 38% (69pts)